Stage III NSCLC RWE in Chinese Patients

Trial Identifier:	D4194R00009
Sponsor:	AstraZeneca
NCTID::	NCT04023812
Start Date:	July 2019
Primary Completion Date:	February 2024
Study Completion Date:	February 2024
Condition:	Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
China, China	Ji nan, China, China, 2501117
China, China	Ji nan, China, China, 2501117
China, China	Ji nan, China, China, 2501117
China, China	Ji nan, China, China, 2501117
China, China	Ji nan, China, China, 2501117
China, China	Ji nan, China, China, 2501117
China, China	Ji nan, China, China, 2501117
China, China	Ji nan, China, China, 2501117
China, China	Ji nan, China, China, 2501117
China, China	Ji nan, China, China, 2501117
China, China	Ji nan, China, China, 2501117
China, China	Ji nan, China, China, 2501117
China, China	Ji nan, China, China, 2501117
China, China	Ji nan, China, China, 2501117
China, China	Ji nan, China, China, 2501117
China, China	Ji nan, China, China, 2501117
China, China	Ji nan, China, China, 2501117
China, China	Ji nan, China, China, 2501117
China, China	Ji nan, China, China, 2501117
China, China	Ji nan, China, China, 2501117
China, China	Ji nan, China, China, 2501117
China, China	Ji nan, China, China, 2501117
China, China	Ji nan, China, China, 2501117
China, China	Ji nan, China, China, 2501117
China, China	Ji nan, China, China, 2501117

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company